Same-session KERARINGS and CXL procedure is effective

Article

Combined use of intracorneal ring segments (KERARINGS) and corneal collagen cross-linking (CXL) in a single session is more effective than performing the procedure in two sessions

A recent study, published in the British Journal of Ophthalmology, has proved that the combined use of intracorneal ring segments (KERARINGS) and corneal collagen cross-linking (CXL) in a single session is more effective than performing the procedure in two sessions.

Professor Tamer M El-Raggal, Magrabi Eye Hospital, Cairo, Egypt, conducted the prospective, comparative study in 16 eyes of 10 patients with progressive mild to moderate keratoconus.

The patients were randomly split into two groups. In the first group, 9 eyes underwent KERARINGS insertion, then CXL 6 months later. The second group involved seven eyes that received both procedures on the same day. A femtosecond laser (Intralase FS 60) was used for channel creation.

Both groups saw a significant improvement in uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA). But same day combination treatment group experienced a more statistically significant decrease in keratometric values.

It was found that both KERARINGS and CXL can be carried out safely in one or two sessions. However, the single-session procedure proved more efficient and successful in improving the corneal shape.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.